PDCD1 and non-small cell lung carcinoma: In this randomized, multicentric Phase II study, 60 patients with NSCLC stage IB to IIIA were randomized to 4 weeks of anti-PD1 antibody nivolumab (arm A) or nivolumab plus anti-LAG-3 (Lymphocyte activation gene-3) antibody relatlimab (arm B) before curative surgery.